Showing 683 results
-
Media Release /- Secukinumab is the first selective IL-17A inhibitor to significantly improve signs and symptoms of ankylosing spondylitis (AS) versus placebo in Phase III studies- Exploratory analyses showed…
-
Media Release /
-
Media Release /- Four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014- Secukinumab is the first selective…
-
Media Release /
-
Media Release /Through music and resources Our Voice in Song™ inspires people living with relapsing MS to become more active managers of their diseaseInitiative launches with nationwide release of "I Can Do This,"…
-
Media Release /
-
Media Release /- Biologics License Application (BLA) for secukinumab, a "first-in-class" IL-17A inhibitor, is currently under FDA review with an anticipated action date in early 2015- FDA Advisory Committee…
-
Media Release /
-
Media Release /- Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL0191- Largest…
-
Media Release /
